Oxymorphone
Oxymorphone (oxymorphone) is a small molecule pharmaceutical. Oxymorphone was first approved as Opana on 1982-01-01. It is used to treat pain in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Oxymorphone (discontinued: Numorphan, Opana, Oxymorphone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Oxymorphone hydrochloride
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| opana | New Drug Application | 2012-01-13 |
| opana er | New Drug Application | 2011-05-31 |
| oxymorphone hydrochloride | ANDA | 2025-08-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pain | EFO_0003843 | D010146 | R52 |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J2410 | Injection, oxymorphone hcl, up to 1 mg |
Clinical
Clinical Trials
35 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic pain | D059350 | — | — | — | 1 | 7 | 2 | 1 | 11 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 2 | — | 1 | 1 | 4 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | 1 | 2 | 3 |
| Narcotic-related disorders | D000079524 | — | — | — | — | — | 1 | 1 | 2 |
| Healthy volunteers/patients | — | — | — | — | — | — | 1 | — | 1 |
| Pathologic constriction | D003251 | — | — | — | — | — | 1 | — | 1 |
| Spinal stenosis | D013130 | EFO_0007490 | M48.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | 3 | 1 | 3 | — | 1 | 8 |
| Postoperative pain | D010149 | — | G89.18 | — | — | 6 | — | — | 6 |
| Neuralgia | D009437 | EFO_0009430 | — | — | — | 1 | — | 1 | 2 |
| Acute pain | D059787 | — | R52 | — | — | 2 | — | — | 2 |
| Cancer pain | D000072716 | — | G89.3 | — | — | 1 | — | 1 | 2 |
| Low back pain | D017116 | — | M54.5 | — | 1 | 1 | — | — | 2 |
| Back pain | D001416 | — | M54 | — | 1 | 1 | — | — | 2 |
| Hernia | D006547 | — | K40-K46 | — | — | 1 | — | — | 1 |
| Chronic disease | D002908 | — | — | — | — | 1 | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Back injuries | D019567 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Personality disorders | D010554 | — | F60.6 | — | — | — | — | 2 | 2 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | — | — | 1 | 1 |
| Vomiting | D014839 | — | R11.1 | — | — | — | — | 1 | 1 |
| Nausea | D009325 | — | R11.0 | — | — | — | — | 1 | 1 |
| Nociceptive pain | D059226 | — | — | — | — | — | — | 1 | 1 |
| Personality | D010551 | EFO_0003947 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Oxymorphone |
| INN | oxymorphone |
| Description | Oxymorphone is a morphinane alkaloid. |
| Classification | Small molecule |
| Drug class | Opioid |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5 |
Identifiers
| PDB | — |
| CAS-ID | 76-41-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL963 |
| ChEBI ID | 7865 |
| PubChem CID | 5284604 |
| DrugBank | DB01192 |
| UNII ID | 9VXA968E0C (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Oxymorphone – Amneal Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Oxymorphone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,134 documents
View more details
Safety
Black-box Warning
Black-box warning for: Opana er, Oxymorphone hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
41,559 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use